SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging following an earnings report that highlighted strong data center growth and optimism regarding AI infrastructure demand, driving significant retail and institutional buzz. While the community is actively debating the sustainability of this rapid upward momentum, many are focused on the stock's role as a major player in the evolving AI compute cycle.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently experiencing significant market divergence, with shareholders expressing frustration as the stock trades sideways while other semiconductor names rally. Community sentiment remains focused on the upcoming earnings call and a potential breakout, despite concerns over short-term price pinning and sector rotation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense buying momentum driven by structural AI demand and a persistent shortage of high-bandwidth memory (HBM). The community is actively debating the stock's long-term valuation relative to its rapid EPS growth, with many investors comparing its current trajectory to previous semiconductor market leaders.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging afterhours as a significant improvement in gross margins and strong earnings per share overshadowed a top-line revenue miss, fueling intense speculation of a major short squeeze. The community is actively debating the company's valuation relative to its peers and the strength of the AI infrastructure demand, with many expressing relief that the focus has shifted back to profitability.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors weigh its aggressive Bitcoin accumulation strategy against a Q1 loss that missed estimates due to unrealized digital asset fluctuations. The community remains polarized, with bulls focused on long-term institutional BTC adoption while bears express skepticism over dilution and the company's heavy reliance on Bitcoin's market performance.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive, parabolic growth fueled by massive demand for AI memory infrastructure and a severe structural shortage of NAND and DRAM chips. While long-term investors celebrate the historic rally, the community is actively debating whether the stock is undergoing an inevitable late-stage climax or if a deeper cyclical re-rating is still in its early innings.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is facing intense volatility as the community remains deeply divided over the company's production execution, ongoing cash burn, and the impact of recent capital raises. While some investors point to strong backing from the PIF and potential growth from new partnerships, others are heavily focused on the stock's recent downtrend and the risk of further dilution, fueling a heated debate between those calling for a short squeeze and those anticipating further downside.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending due to intense community speculation regarding upcoming regulatory catalysts, including a potential FDA decision on the sBLA and imminent updates from major global markets like Japan and Saudi Arabia. Investors are closely monitoring the CEO's uncharacteristic silence ahead of earnings, interpreting it as a strategic move while focusing on the stock's high short interest as a setup for a potential squeeze.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Semiconductor bears are feeling the intense pressure of a relentless, momentum-driven bull market that continues to ignore geopolitical risks and valuation concerns, leaving investors torn between capitulation and holding out for a long-awaited reversal. The community is actively debating the sustainability of the current melt-up, with many traders frustrated by consistent after-hours rallies and a persistent disconnect between sector earnings and price action.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is surging as the community reacts to a multi-billion dollar master services agreement with AI infrastructure firm Cerebras, fueling excitement for the upcoming IPO and potential for long-term re-rating. Bulls are actively advocating for holding through volatility, viewing the deal as a major validation of the company's data center capacity, while discussions frequently highlight ongoing short interest and the strategic importance of this new partnership for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

210,831 Shares in CorMedix Inc $CRMD Acquired by Del Sette Capital Management LLC

Del Sette Capital Management LLC acquired a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund...

CorMedix (CRMD) Expected to Announce Earnings on Wednesday

CorMedix (NASDAQ:CRMD) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

CorMedix (NASDAQ:CRMD) Earns Market Outperform Rating from Citizens Jmp

Citizens Jmp restated a "market outperform" rating and set a $19.00 price target on shares of CorMedix in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $14.00

Leerink Partners boosted their price objective on shares of CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a research note on Tuesday...

CorMedix (NASDAQ:CRMD) Price Target Raised to $15.00

Needham & Company LLC raised their price target on shares of CorMedix from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday...

<ul class="summary-bullets"><li>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections.</li><li>Rezzayo is already approved in the U.S. for the treatment of candidemia and invasive candidiasis in adults.</li><li>The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.</li></ul>Shares of CorMedix Therapeutics (CRMD) rose 2% on Monday after the company announced positive results from its late-stage trial evaluating its antifungal drug Rezzayo to prevent invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Allogeneic hematopoietic stem cell transplantation is a curative procedure for high-risk blood cancers and marrow diseases, where healthy blood-forming cells from a donor replace a patient's diseased marrow. Patients undergoing the procedure face prolonged periods where their immunity is not strong enough to ward off infections from fungi, including candida, aspergillus, and pneumocystis.Rezzayo is already approved in the U.S. for the treatment of fungal infections, candidemia, and invasive candidiasis in adults. The company estimated that the potential US market opportunity for Rezzayo in preventative care exceeds $2 billion.<h2 class="st-heading-2">Trial Takeaways</h2>In the trial, aimed at evaluating the safety and efficacy of once-weekly Rezzayo, the drug demonstrated a profile comparable with standard antimicrobial regimen in reducing the incidence of invasive fungal infections, the company said. Fungal-free survival at day 90 was 60.7% in the Rezzayo group versus 59.0% in the group that received a standard antimicrobial regimen, it added.Furthermore, the drug was well tolerated with a safety profile showing a favorable benefit/risk profile in the patient population, the company said, while adding that the drug also demonstrated fewer interactions with other drugs and discontinuations due to toxicity.CorMedix now expects to have a meeting with the U.S. Food and Drug Administration in the coming months before submitting an application for the drug for the indication. The company expects to file the application in the second half of 2026 based on the trial results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CRMD jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels. According to internal data, retail chatter around the stock jumped 1400% over the past day.A Stocktwits user expressed optimism for the stock rising into earnings while adding that “today was great news.”<stembedurl>https://www.stocktwits.com/S2730/message/651521499</stembedurl>Another user expressed muted enthusiasm, opining that the results, though good, are not “transformative.”<stembedurl>https://www.stocktwits.com/ReturnOfEsquire/message/651515352</stembedurl> <a href="https://stocktwits.com/symbol/CRMD">CRMD stock</a> has fallen 17% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sndk-stock-surges-nearly-8-to-hit-fresh-record-high-what-s-behind-the-investor-optimism-april-27/cZBND2dReP8">SNDK Stock Surges Nearly 8% To Hit Fresh Record High – What’s Behind The Investor Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market 

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 

Equity

CorMedix now expects to meet with the U.S. Food and Drug Administration in the coming months. 


CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study

CorMedix says Phase 3 ReSPECT data show rezafungin is non-inferior in fungal prevention, supporting FDA filing plans and a $2 billion market outlook.read more...

CorMedix (NASDAQ:CRMD) Earns Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of CorMedix in a research note on Monday...

Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD

Phocas Financial Corp. bought a new position in shares of CorMedix Inc (NASDAQ:CRMD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

CorMedix Outlines Post-Melinta Growth, Q2 REZZAYO Phase 3 Catalyst and DefenCath Reimbursement Shift

CorMedix (NASDAQ:CRMD) Chief Executive Officer Joe Todisco outlined the company's evolving strategy and upcoming catalysts during a fireside chat at Needham & Company's 25th Annual Healthcare...

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest CRMD News

CRMDCorMedix Inc